See more : Inspirato Incorporated (ISPOW) Income Statement Analysis – Financial Results
Complete financial analysis of Vor Biopharma Inc. (VOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vor Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ain Holdings Inc. (9627.T) Income Statement Analysis – Financial Results
- Nifco Inc. (NIFCY) Income Statement Analysis – Financial Results
- Swelect Energy Systems Limited (SWELECTES.NS) Income Statement Analysis – Financial Results
- Strategic Metals Ltd. (SMDZF) Income Statement Analysis – Financial Results
- VPC Impact Acquisition Holdings II (VPCBW) Income Statement Analysis – Financial Results
Vor Biopharma Inc. (VOR)
About Vor Biopharma Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| Gross Profit | -3.49M | -8.96M | -4.45M | -1.39M | -91.00K | -20.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 94.32M | 64.55M | 47.53M | 31.62M | 6.20M | 2.43M |
| General & Administrative | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 31.72M | 28.87M | 21.49M | 11.75M | 4.22M | 427.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Cost & Expenses | 126.04M | 93.42M | 69.02M | 43.37M | 10.42M | 2.86M |
| Interest Income | 8.17M | 1.32M | 119.00K | 29.00K | 154.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 1.00M |
| Depreciation & Amortization | 3.49M | 8.96M | 4.45M | 1.39M | 91.00K | 20.00K |
| EBITDA | -114.37M | -90.89M | -67.58M | -41.95M | -10.17M | -2.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -126.04M | -93.42M | -69.02M | -43.37M | -10.42M | -2.86M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.17M | 1.32M | 119.00K | 29.00K | -422.00K | -1.29M |
| Income Before Tax | -117.86M | -92.09M | -68.90M | -43.34M | -10.84M | -4.15M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.32M | -119.00K | 427.70K | 608.00K | -289.00K |
| Net Income | -117.86M | -90.77M | -68.78M | -43.34M | -11.45M | -4.15M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| EPS Diluted | -1.75 | -2.29 | -1.85 | -1.17 | -0.31 | -0.73 |
| Weighted Avg Shares Out | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
| Weighted Avg Shares Out (Dil) | 67.19M | 39.55M | 37.17M | 37.13M | 37.12M | 5.66M |
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of...
Vor Biopharma: Targeted Therapies For Transplants
Vor Biopharma: Targeted Therapies For Transplants
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combination with targeted therapies for the treatment of cancer, today...
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Robert...
Vor Reports Fiscal Year 2020 Financial Results
IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML
Vor Biopharma to Present at the Barclays Global Healthcare Conference
CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating...
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating...
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the closing of its previously announced...
VOR Stock Price Increased 108.33%: Why It Happened
The stock price of Vor Biopharma Inc. (NASDAQ: VOR) increased by 108.33% on Friday, February 5. This is why it happened.
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion...
Source: https://incomestatements.info
Category: Stock Reports